by | Jan 9, 2025 | Lupus Foundation of America
We understand the incredible stress, uncertainty and emotional distress that a natural disaster causes those affected by it. As wildfires continue to impact the Southern California region, we wanted to provide a list of resources and information for those who are...
by | Jan 8, 2025 | Lupus Foundation of America, News & Events
In the Phase 2b CARE study, the investigational drug, cenerimod, demonstrated safe and effective results for treatment of adults with moderate-to-severe systemic lupus erythematosus (SLE). The drug’s multifaceted immunomodulatory properties target key aspects of SLE...
by | Jan 3, 2025 | Lupus Foundation of America
There are so many ways that LFA donors, fundraisers, advocates and volunteers changed the lives of people with lupus and their loved ones last year, including:Fueling Pioneering Lupus Research: Donors’ generosity in 2024 enabled us to fund groundbreaking research with...
by | Dec 30, 2024 | Lupus Foundation of America, News & Events
A new study explored the potential of IncRNA CASC2 and miR-155 levels as non-invasive diagnostic biomarkers for systemic lupus erythematosus (SLE) and lupus nephritis (LN). Previous studies have found a connection between RNA and SLE. The study included 90...
by | Dec 27, 2024 | Lupus Foundation of America, News & Events
In a new study published in Lupus Science & Medicine, researchers explored the efficacy of using a combination of belimumab and standard immunotherapy compared to standard immunotherapy alone in children newly-diagnosed with childhood-onset lupus nephritis...
by | Dec 23, 2024 | Lupus Foundation of America, News & Events
In a new study, the drug, deucravacitinib, proved to be a safe and more effective treatment for cutaneous lupus erythematosus disease (CLE, lupus skin disease) than two other commonly used therapies, anifrolumab and litifilimab. Lupus affects people differently, but...
